Psyence Biomedical Ltd.
PBM
$5.21
-$0.445-7.88%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 825.40K | 825.40K | 890.50K | 832.90K | 562.40K |
| Depreciation & Amortization | 1.20K | 1.20K | 1.00K | 900.00 | 100.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 864.90K | 864.90K | 1.16M | 966.60K | 644.10K |
| Operating Income | -864.90K | -864.90K | -1.16M | -966.60K | -644.10K |
| Income Before Tax | -974.40K | -974.40K | 141.50K | 1.48M | -24.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -974.40K | -974.40K | 141.50K | 1.48M | -24.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -974.40K | -974.40K | 141.50K | 1.48M | -24.78M |
| EBIT | -864.90K | -864.90K | -1.16M | -966.60K | -644.10K |
| EBITDA | -863.70K | -863.70K | -1.16M | -965.70K | -644.10K |
| EPS Basic | -2.73 | -2.73 | 4.07 | 51.14 | -1.11K |
| Normalized Basic EPS | -1.40 | -1.40 | -26.00 | -15.94 | -8.73 |
| EPS Diluted | -2.73 | -2.73 | 4.06 | 51.13 | -1.11K |
| Normalized Diluted EPS | -1.40 | -1.40 | -25.99 | -15.94 | -8.73 |
| Average Basic Shares Outstanding | 357.10K | 357.10K | 34.70K | 28.90K | 22.40K |
| Average Diluted Shares Outstanding | 357.10K | 357.10K | 34.70K | 29.00K | 22.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |